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Abstract Poly(ADP-ribose) polymerase (PARP) is a nuclear
enzyme, which is activated by DNA strand breaks. Although
PARP is known to be cleaved by the cysteine protease, caspase-
3/CPP32, during apoptosis, signal cascade which regulates the
PARP activity has not been fully understood. In this study, we
investigated post-translational modification of PARP. We found
that PARP was phosphorylated by a serine kinase in vivo. PARP
was activated temporarily and extensive auto-modification
occurred on PARP, possibly by the fragmented DNA during
apoptosis induced by etoposide in Jurkat cells. However, the
phosphorylation level was not changed for up to 6 h, after PARP
cleavage began in apoptosis by the treatment with etoposide.
Furthermore, we showed the presence of a PARP-associated
kinase in nuclear extracts of the HTLV-I infected T-cell lines but
not in uninfected T-cell lines, whereas this kinase did not inhibit
the PARP activity even in the presence of ATP. Taken together,
in vivo phosphorylation of PARP might be independent of the
activation or cleavage of PARP.
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1. Introduction
Poly(ADP-ribose) polymerase (PARP, EC 2.4.2.30) is a
DNA repair enzyme, which binds to and is activated by
DNA strand breaks generated by ionizing radiation or alky-
lating agents. PARP catalyzes the transfer of ADP-ribose
units from its substrate, nicotinamide adenine dinucleotide
(NAD), to nuclear proteins such as histones and PARP itself
[1^3]. PARP has been implicated in DNA repair and genomic
stability [4^7].
Several proteases related to interleukin-1L-converting en-
zyme (ICE) and the product of the Caenorhabditis elegans
ced-3 are activated and required during apoptosis. PARP is
cleaved into an 89-kDa carboxy-terminal fragment containing
the auto-modi¢cation domain and the NAD-binding domain
and an approximately 24-kDa N-terminal fragment contain-
ing the DNA binding domain by a cysteine protease, caspase-
3/prICE/CPP32/Yama/apopain and Mch3 during apoptosis
[8,9]. PARP cleavage can also be mediated by Nedd2, ICE,
TX and Mch2, with lower e⁄ciency [10]. Therefore, PARP
may be selectively targeted for degradation during apoptosis.
However, little is known about the signalling pathway which
regulates the PARP activity. Here, we report that PARP was
phosphorylated by a serine kinase in vivo. Although PARP
was activated temporarily, the phosphorylation level was not
changed, even when PARP cleavage began in apoptosis by the
treatment with etoposide, suggesting that the phosphorylation
of PARP did not coincide with the temporary activation or
cleavage of PARP during apoptosis. Furthermore, we found a
PARP associated kinase in the HTLV-I infected T-cell lines,
whereas this kinase did not inhibit the PARP activity.
2. Materials and methods
2.1. Cell culture and metabolic labelling
JPX-9 cell was a kind gift from Dr. K. Sugamura [11]. Jurkat, JPX-
9, MT-2, MT-4 and HUT102 cells were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum
(FCS) at 37‡C in a humidi¢ed 5% CO2 atmosphere. For metabolic
labelling, Jurkat cells were incubated in phosphate-free RPMI 1640
medium supplemented with 10% FCS dialyzed against Tris-bu¡ered
saline (20 mM Tris-HCl, 0.15 M NaCl, pH 7.5) containing
[32P]orthophosphate (ICN, 18.5 Mbq/ml) at 37‡C for 8 h. During
metabolic labelling, cells were treated with 100 WM etoposide for
the indicated time. For the expression of the Tax protein, JPX-9 cells
were cultured in the presence of 10 WM CdCl2 at 37‡C for 3 days.
2.2. Immunoblotting analysis
Cells were lysed in the lysis bu¡er containing 50 mM Tris-HCl (pH
8.0), 150 mM NaCl, 4 mM EDTA, 1% NP-40, 0.1% SDS, 1 mM DTT
and 1 mM PMSF. The lysate was subjected to SDS-PAGE, followed
by immunoblotting analysis using polyclonal antibody against PARP
or poly(ADP-ribose) antibody.
2.3. Immunoprecipitation
32P-labelled Jurkat cells were lysed in the special RIPA bu¡er con-
taining 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1%
NP-40, 0.1% SDS, 0.1% sodium deoxycholate, 50 mM NaF, 0.2 mM
Na3VO4, 10 mM L-glycerophosphate, 1 mM PMSF and 1 Wg/ml
aprotinin. The lysates were pre-cleared with a protein G-Sepharose
(Pharmacia) coated with normal rabbit IgG and the supernatant was
incubated with anti-PARP polyclonal antibody for 60 min at 4‡C. The
precipitates were washed four times with the RIPA bu¡er. After elu-
tion of protein in 1U Laemmli sample bu¡er containing 50 mM Tris-
HCl (pH 6.8), 2% SDS, 0.1% bromophenol blue (BPB), 10% glycerol
and 5% 2-mercaptoethanol with boiling for 5 min, samples were frac-
tionated on a 7% SDS-polyacrylamide gel and detected by autora-
diography.
2.4. Induction of apoptosis
Jurkat cells were induced to undergo apoptosis by exposure to
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100 WM etoposide. For analysis of DNA fragmentation, Jurkat cells
treated with 100 WM etoposide were collected at the indicated time,
washed with ice-cold PBS, and lysed in 500 Wl of a lysis bu¡er con-
taining 5 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 0.5% Triton
X-100. After 10 min on ice, the lysates were centrifuged (13 000Ug)
for 10 min at 4‡C to separate the soluble fragmented DNA from
insoluble intact chromatin. The supernatant was treated with protein-
ase K (200 Wg/ml) in the presence of 1% SDS overnight at 37‡C. Then
the lysates were extracted with phenol-chloroform-isoamyl alcohol
(24:1), and the aqueous phase was made to 300 mM NaCl and 2 vol-
umes of ethanol were added. The pellet was rinsed with 70% ethanol,
air dried, and dissolved in 15 Wl of the bu¡er containing 10 mM Tris-
HCl, 1 mM EDTA (pH 8.0) and RNase A (0.6 mg/ml). After incu-
bation at 37‡C for 30 min, the samples were electrophoresed on a 2%
agarose gel. This procedure could isolate the low molecular weight
degraded DNA without high molecular weight intact DNA.
2.5. Phospho-amino acid analysis
32P-labelled PARP protein was eluted from acrylamide gel sections
in the elution bu¡er containing 50 mM NH4HCO3 and 0.1% SDS.
Recovered protein sample was hydrolyzed in 6 N HCl at 110‡C for
90 min. Resulting phospho-amino acid samples were mixed with
standards (phospho-serine, phospho-threonine and phospho-tyrosine;
2 Wg each) and applied onto a cellulose thin layer glass plate (20U20
cm, Merck Art. 5716). High voltage electrophoresis was performed in
pH 3.5 bu¡er (pyridine/acetic acid/water, 1:10:189 (v/v)) at 4‡C. 32P-
labelled phospho-amino acids were identi¢ed by autoradiography and
phospho-amino acid standards were identi¢ed by spraying the plate
with ninhydrin.
2.6. In vitro kination and PARP assay
Nuclear extracts were immunoprecipitated with anti-PARP anti-
body in the lysis bu¡er containing 10 mM Tris-HCl (pH 8.0), 150
mM NaCl, 2 mM EGTA, 50 mM NaF, 10 mM L-glycerophosphate,
10 Wg/ml aprotinin, 1 mM PMSF, 1 mM dithiothreitol (DTT) and 1%
NP-40. The anti-PARP immunoprecipitates were incubated with
[Q-32P]ATP with or without poly(dI-dC)Wpoly(dI-dC) (0.2 Wg, Pharma-
cia) in the assay bu¡er containing 10 mM HEPES (pH 7.9), 50 mM
NaCl, 10 mM MgCl2, 5% glycerol, 1 mM EGTA and 1 mM dithio-
threitol (DTT) in a ¢nal reaction volume of 30 Wl. After incubation at
30‡C for 10 min, the reaction mixture was subjected to SDS-PAGE.
Phosphorylation was detected by autoradiography.
For the PARP assay, the anti-PARP immunoprecipitates were in-
cubated with [32P]NAD with or without poly(dI-dC)Wpoly(dI-dC)
(0.2 Wg) in the assay bu¡er containing 10 mM HEPES (pH 7.9),
50 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM EGTA and 1 mM
DTT in a ¢nal reaction volume of 30 Wl. After incubation at 30‡C for
10 min, the reaction mixture was subjected to SDS-PAGE, and poly-
(ADP-ribosyl)ation was detected by autoradiography. To study the
e¡ect of the phosphorylation on the PARP activity, the reaction mix-
ture was also incubated with unlabelled 0.2 mM ATP.
3. Results
3.1. In vivo phosphorylation of PARP
Previously Tanaka et al. [12] reported that PARP was phos-
phorylated by protein kinase C (PKC) in vitro [12], however,
little is known about the in vivo phosphorylation of PARP.
To determine whether PARP was phosphorylated in vivo,
Jurkat cells were metabolically radio-labelled with
[32P]orthophosphate for 8 h. PARP phosphorylation was an-
alyzed by SDS-PAGE of anti-PARP immunoprecipitates. We
observed that PARP was phosphorylated in vivo (Fig. 1a). To
identify the phosphorylated amino acids in PARP, 32P-la-
belled PARP protein from Jurkat cells as shown in Fig. 1a
was eluted from a gel section and subjected to acid hydrolysis.
[32P]Phospho-amino acids were separated by high voltage
electrophoresis and detected by autoradiography. We found
that the PARP protein was phosphorylated mainly at the
serine residue (Fig. 1b), suggesting that PARP was phos-
phorylated by a serine kinase in vivo.
3.2. Temporary activation and phosphorylation of PARP
during apoptosis
PARP has so far been shown to be cleaved by the cysteine
protease, caspase-3/CPP32, during apoptosis. The topoisomer-
ase II inhibitor, etoposide, is a potent inducer of apoptosis in
mouse thymocytes and HL-60 human leukemia cells [13]. To
study the time course of proteolytic cleavage and phosphoryl-
ation of PARP, Jurkat human T-cells were exposed to 100
WM etoposide for the indicated time (Fig. 2a), and then whole
cell extracts were prepared and subjected to immunoblotting
analysis. Immunoblotting with antibody against PARP re-
vealed that PARP was cleaved to make an 89-kDa polypep-
tide in 6 h after the treatment (Fig. 2a).
We also noticed that the 115-kDa PARP band altered its
electrophoretic mobility and smeared to a slower migrating
size after 6 h of treatment of Jurkat cells with 100 WM etopo-
side (Fig. 2a). However, this alteration of the migration pat-
tern declined in 24 h after the treatment. To determine
whether the slower migrating PARP was the result of auto-
modi¢cation of poly(ADP-ribosyl)ation, we performed immu-
noblotting analysis with the antibody against poly(ADP-ri-
bose). We observed weak poly(ADP-ribosyl)ation of PARP
at 0 and 2 h after the treatment and much stronger poly-
(ADP-ribosyl)ation at 6 h, which also paralleled with DNA
fragmentation (Fig. 2b,c). The level of auto-modi¢ed PARP
decreased in 24 h after the treatment. These results suggests
that PARP was activated temporarily (at 6 h after etoposide
treatment) by fragmented DNA during apoptosis.
To determine whether the phosphorylation of PARP is cor-
related with the temporary activation or cleavage of PARP
during apoptosis, cells were treated with or without 100 WM
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Fig. 1. In vivo phosphorylation of PARP. a: Jurkat cells were la-
belled with [32P]orthophosphate (ICN, 18.5 Mbq/ml) for 8 h. 32P-la-
belled Jurkat cells were lysed, and then immunoprecipitation was
performed with antibody against PARP. PARP phosphorylation
was analyzed by SDS-PAGE of anti-PARP immunoprecipitates and
detected by autoradiography. b: Phospho-amino acid analysis of
PARP. 32P-labelled PARP protein from Jurkat cells as shown in a
was eluted from acrylamide gel sections. Recovered protein sample
was hydrolyzed in 6 N HCl at 110‡C for 90 min. Resulting phos-
pho-amino acid samples were mixed with phospho-amino acid
standards and applied onto a cellulose thin layer glass plate. High
voltage electrophoresis was performed in pH 3.5 bu¡er at 4‡C. 32P-
labelled phospho-amino acids were identi¢ed by autoradiography.
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etoposide for the time indicated in Fig. 2d, during the meta-
bolic labelling. PARP phosphorylation was analyzed by SDS-
PAGE of anti-PARP immunoprecipitates. We observed that
PARP was phosphorylated with (2, 4 and 6 h) or without 100
WM etoposide (0 h) (Fig. 2d). The phosphorylation level of
PARP was not changed for up to 6 h of treatment with etopo-
side. And the levels of the 32P-labelled bands were slightly
declined at 6 h, suggesting that the phosphorylation of
PARP did not coincide with the temporary activation or
cleavage of PARP during apoptosis.
3.3. PARP associated kinase is independent of the activation of
PARP
To further con¢rm the in vivo phosphorylation of PARP,
immunoprecipitates of the nuclear extracts of several unla-
belled human T-cell lines with antibody against PARP were
incubated with [Q-32P]ATP without dsDNA, and then the re-
action mixture was subjected to SDS-PAGE. We observed a
phosphorylated PARP in HTLV-I infected T-cell lines, MT-2,
MT-4 and HUT102 cells (Fig. 3a, lanes 4^6; Fig. 3c, lanes 1
and 2), but not in uninfected cell lines, Jurkat and JPX-9 cells
(Fig. 3a, lanes 1^3; Fig. 3b, lanes 1 and 2), suggesting the
presence of an unidenti¢ed PARP-associated kinase in the
nuclear extracts of HTLV-I infected T-cell lines. Moreover,
PARP was strongly phosphorylated in MT-2 cells compared
with MT-4 and HUT102 cells (Fig. 3a, lane 4; Fig. 3c, lanes 1
and 2). The phosphorylation level was not increased by the
addition of dsDNA (Fig. 3c, lane 2), suggesting that PARP
was phosphorylated in a dsDNA independent manner. We
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Fig. 3. The presence of a PARP-associated kinase in HTLV-I in-
fected T-cell lines. a: PARP was isolated from the nuclear extracts
of several unlabelled cell lines, HTLV-I uninfected Jurkat (lane 1)
and JPX-9 without (lane 2) or with 10 WM CdCl2 (lane 3) or
HTLV-I infected MT-2 (lane 4), MT-4 (lane 5) and HUT102 cells
(lane 6), by immunoprecipitation with anti-PARP antibody. The
anti-PARP immunoprecipitates were incubated with [Q-32P]ATP
without dsDNA. The reaction mixture was subjected to SDS-
PAGE. Phosphorylated PARP was detected by autoradiography.
b and c: The anti-PARP immunoprecipitates of Jurkat (b) or MT-2
cells (c) were incubated with [Q-32P]ATP with or without poly-
(dI-dC)Wpoly(dI-dC). The reaction mixture was subjected to SDS-
PAGE. Phosphorylation was detected by autoradiography (b and c,
lanes 1 and 2). For the PARP assay, the anti-PARP immunoprecipi-
tates were incubated with [32P]NAD with or without poly(dI-dC)Wpo-
ly(dI-dC). The reaction mixture was subjected to SDS-PAGE, and
poly(ADP-ribosyl)ation was detected by autoradiography (b and c,
lanes 3^5). To study the e¡ect of the phosphorylation on PARP ac-
tivity, the reaction mixture was also incubated with unlabelled
0.2 mM ATP (b and c, lane 5).
Fig. 2. Temporary activation and phosphorylation of PARP during
apoptosis induced by etoposide in Jurkat cells. a: Time course of
cleavage of PARP after treatment of Jurkat cells with etoposide
(100 WM). PARP was detected by immunoblotting with antibody
against PARP. Asterisk indicates the cleaved 89-kDa fragment. b:
Time course of PARP activation after treatment of Jurkat cells with
etoposide (100 WM). Auto-modi¢cation of PARP was detected by
immunoblotting with polyclonal antibody against poly(ADP-ribose).
c: Time course of DNA fragmentation after treatment of Jurkat
cells with etoposide (100 WM). VH and M indicate bacteriophage
VDNA digested by HindIII and BX174 DNA digested by HincII
used as size markers of DNA, respectively. d: Time course of the in
vivo phosphorylation of PARP after treatment of Jurkat cells with
etoposide (100 WM). Jurkat cells were labelled with
[32P]orthophosphate for 8 h. During the metabolic labelling, cells
were also treated without (0 h) or with 100 WM etoposide for the
indicated time (2, 4 and 6 h). PARP phosphorylation was analyzed
by SDS-PAGE of anti-PARP immunoprecipitates and detected by
autoradiography.
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also observed that the phosphorylation of PARP is sensitive
to calf intestine alkaline phosphatase (data not shown). How-
ever, we could not detect the kinase in the CdCl2 treated JPX-
9 cells, which expresses the Tax oncoprotein (Fig. 3a, lane 3),
suggesting that the HTLV-I Tax protein could not directly
induce the kinase. Furthermore, the e¡ect of the phosphoryl-
ation of PARP by the PARP-associated kinase on the PARP
activity was examined. Anti-PARP immunoprecipitates from
nuclear extracts of Jurkat or MT-2 cells were incubated with
or without dsDNA in the presence of [32P]NAD, and then the
total mixture was subjected to SDS-PAGE, followed by
autoradiography. PARP was strongly activated to produce
poly(ADP-ribose) in the presence of dsDNA (Fig. 3b,c, lanes
3 and 4). This PARP activity was not inhibited by the kinase
even in the presence of unlabelled ATP (Fig. 3, lane 5), sug-
gesting that the phosphorylation of PARP by the PARP-as-
sociated kinase does not interfere with the activation of
PARP.
4. Discussion
The signal cascade which regulates PARP activity has not
been fully understood. In this study, we have ¢rst demon-
strated that PARP was phosphorylated by an unidenti¢ed
serine kinase in vivo. Previously other groups reported that
PARP is phosphorylated by protein kinase C (PKC) in vitro
[12] and PKC inhibits the DNA binding activity of PARP
[14]. Recently, we have found that DNA-PK phosphorylates
PARP in a dsDNA-dependent manner in vitro (Ariumi et al.,
unpublished manuscript). Moreover, we have found a PARP
associated kinase in anti-PARP immunoprecipitates of nu-
clear extracts of HTLV-I infected T-cell lines. Although we
demonstrated in vivo phosphorylation of PARP in Jurkat
cells, we did not observe the PARP associated kinase, suggest-
ing that several kinases phosphorylate PARP. While the
PARP associated kinase phosphorylated PARP in a
dsDNA-independent manner, the PARP activity was not in-
hibited by this kinase, suggesting that the kinase might not be
conventional PKC (cPKC) or DNA-PK. In this regard, we
could not completely exclude the possibility in this study that
the apparent enzyme activity of PARP might not be inhibited
if the unphosphorylated PARP is present and shows enough
activity. However, we observed auto-modi¢cation of recombi-
nant PARP protein expressed in E. coli, suggesting that the
phosphorylation of PARP is dispensable in auto-modi¢cation
(data not shown). Interestingly, we have found the PARP
associated kinase in the HTLV-I infected T-cell lines but
not in uninfected T-cell lines, suggesting that HTLV-I infec-
tion induces this kinase. However, we could not detect the
kinase in the CdCl2 treated JPX-9 cells, which expresses the
Tax oncoprotein, suggesting that the HTLV-I Tax protein
could not directly induce the kinase. We are currently study-
ing the biological signi¢cance of the kinase in the HTLV-I
infection.
Recent studies have demonstrated that the ICE protease
family plays an important role in apoptosis. The proteins
shown to be in vitro targets for an identi¢ed ICE-like protease
are two DNA repair enzymes, i.e. PARP [8^10] and DNA-PK
[13,15]. We have also observed that both DNA-PKcs and
PARP cleavage began at the same time (2.5 h) when apoptosis
started by etoposide in Jurkat cells (data not shown). Further-
more, we have found that PARP was activated and extensive
auto-modi¢cation occurred on PARP, paralleled with the
progress of DNA fragmentation, suggesting activation of
PARP by the fragmented DNA. For each ADP-ribosylation
conducted by PARP, one molecule of NAD is consumed and
an equivalent of four molecules of adenosine triphosphate
(ATP) is required to regenerate NAD from nicotinamide.
Thus, the extensive synthesis of poly(ADP-ribose) in response
to DNA damage causes a temporary reduction of the cellular
NAD pool. In this regard, Zhang et al. [16] suggested a model
in nitric oxide (NO) induced neurotoxicity. NO, a free radical,
triggers DNA damage which in turn activates PARP, which
ultimately depletes energy sources from the cell and leads to
cell death [16]. Similarly, the rapid PARP activation during
apoptosis may deplete the NAD pool in the cell and may
participate in the cell death. Moreover, Vaziri et al. [17] re-
ported that inhibition of PARP activity leads to extension of
cellular life span [17]. PARP associates with p53 and activates
it post-translationally. Inhibition of PARP activity leads to
abrogation of p21 and mdm2 expression in response to
DNA damage. Recently, Wang et al. [7] reported that
PARP is important for genomic stability but dispensable in
apoptosis using the primary PARP3=3 cells, suggesting that
PARP is not directly involved in apoptosis [7]. In contrast,
Simbulan-Rosenthal et al. [18] demonstrated that the immor-
talized PARP3=3 ¢broblasts exhibited neither any of the bio-
chemical nor morphological changes characteristic of apopto-
sis when exposed to anti-Fas and cycloheximide and stable
transfection of PARP3=3 ¢broblasts with wild-type PARP
rendered the cells sensitive to Fas-mediated apoptosis, sug-
gesting that PARP may trigger key steps in the apoptotic
program [18].
Taken together, PARP was identi¢ed as a phosphoprotein
in vivo and in vitro; however, in vivo phosphorylation of
PARP was independent of the activation of PARP. It remains
to clarify the biological signi¢cance of in vivo phosphoryla-
tion of PARP. Further identi¢cation of the PARP kinase
would provide a clue to understanding how PARP is involved
in DNA repair and apoptosis.
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